The United Kingdom is witnessing a growing surge in interest surrounding copyright substances. Beyond the familiar use of psilocybin and LSD, investigators and explorers are increasingly exploring less-charted areas, particularly the copyright compound and the nascent cannabinoid, cannabigerol. This burgeoning community encompasses clinical trials